Picture of IBEX Technologies logo

IBT IBEX Technologies Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Momentum

Relative Strength (%)
1m+25.11%
3m+65.15%
6m+14.78%
1yr+64.53%
Volume Change (%)
10d/3m+158.18%
Price vs... (%)
52w Highn/a
50d MA+19.24%
200d MA+36.45%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value2.45
Price to Tang. Book2.45
Price to Free Cashflow34.22
Price to Sales4.49
EV to EBITDA13.99

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital9.74%
Return on Equity32.7%
Operating Margin19.58%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Jul 202431st Jul 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of IBEX Technologies EPS forecast chart

Profile Summary

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.’s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA’s) for pre-clinical research. The Company has developed a proprietary expression for the production of its enzymes in Flavobacterium heparinum. This expression system allows for producing each glycosaminoglycan (GAG) enzyme separately from other enzymes therefore achieving the highest purity using a well-defined proprietary purification scheme. The Company operates in one industry segment: the production and sale of diagnostic products.

Directors

Last Annual
July 31st, 2023
Last Interim
October 31st, 2023
Incorporated
September 2nd, 1977
Public Since
November 14th, 1985
No. of Employees
15
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconTSX Venture Exchange
Shares in Issue
24,507,644

IBT Share Price Performance

Upcoming Events for IBT

Q2 2024 IBEX Technologies Inc Earnings Release

IBEX Technologies Inc Annual Shareholders Meeting

IBEX Technologies Inc Extraordinary Shareholders Meeting

Q3 2024 IBEX Technologies Inc Earnings Release

Similar to IBT

Picture of Arch Biopartners logo

Arch Biopartners

ca flag iconTSX Venture Exchange

Picture of biOasis Technologies logo

biOasis Technologies

ca flag iconTSX Venture Exchange

Picture of Ceapro logo

Ceapro

ca flag iconTSX Venture Exchange

Picture of Covalon Technologies logo

Covalon Technologies

ca flag iconTSX Venture Exchange

Picture of Hemostemix logo

Hemostemix

ca flag iconTSX Venture Exchange

FAQ